Earnings Feed
Start Free
BIO-TECHNE Corp·4

Apr 24, 6:06 PM ET

Kelderman Kim 4

4 · BIO-TECHNE Corp · Filed Apr 24, 2026

Research Summary

AI-generated summary of this filing

Updated

Bio-Techne CEO Kim Kelderman Exercises Options, Sells 1,363 Shares

What Happened
Kim Kelderman, CEO of Bio‑Techne Corp (TECH), exercised or converted derivative awards for 11,344 shares on 2026-04-22. The filing shows 11,344 shares acquired at $0.00 per share (reporting code M). To cover tax obligations, 1,363 shares were surrendered/withheld (reporting code F) at an indicated value of $58.58 per share, totaling about $79,845. Net shares received from the transaction = 11,344 − 1,363 = 9,981 shares.

Key Details

  • Transaction date: 2026-04-22; Form 4 filed 2026-04-24 (timely filing).
  • Exercise/Conversion (M): 11,344 shares acquired at $0.00 per share.
  • Tax withholding/payment (F): 1,363 shares disposed/withheld at $58.58 per share = $79,845.
  • Net shares retained after withholding: 9,981 (11,344 − 1,363).
  • Footnote F indicates shares were used to satisfy tax obligations; other listed footnotes in the filing relate to vesting schedules of outstanding awards.
  • No late filing flagged in this report.

Context

  • This was an exercise/conversion of a derivative award reported at $0.00 per share; the simultaneous withholding/sale of shares to satisfy taxes (code F) is a common administrative step and does not necessarily signal a broader buying or selling intent.
  • For retail investors, exercises with partial withholding are routine—what matters more is whether executives are buying shares with cash or selling shares for cash beyond tax withholding. In this filing, the only sale reported was the withholding to meet taxes.

Insider Transaction Report

Form 4
Period: 2026-04-22
BIO-TECHNE CorpTECH
Kelderman Kim
DirectorChief Executive Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2026-04-22+11,344→ 64,421 total
  • Tax Payment

    Common Stock

    2026-04-22$58.58/sh−1,363$79,845→ 63,058 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F1]
    2026-04-22−11,344→ 61,692 total
    Exercise: $47.60Exp: 2026-08-07→ Common Stock (11,344 underlying)
Holdings

  • Stock Option (Right to Buy)

    [F1]
    Exercise: $66.97Exp: 2027-08-05→ Common Stock (115,724 underlying)
    115,724

  • Stock Option (Right to Buy)

    [F1]
    Exercise: $120.46Exp: 2028-08-06→ Common Stock (25,944 underlying)
    25,944

  • Stock Options (Right to Buy)

    [F1]
    Exercise: $94.52Exp: 2029-08-15→ Common Stock (28,940 underlying)
    28,940

  • Performance Restricted Stock Units

    [F2][F3]
    → Common Stock (8,873 underlying)
    8,873

  • Performance Stock Options (Right to Buy)

    [F3]
    Exercise: $84.61Exp: 2030-08-15→ Common Stock (23,881 underlying)
    23,881

  • Stock Options (Right to Buy)

    [F4]
    Exercise: $84.61Exp: 2030-08-15→ Common Stock (29,391 underlying)
    29,391

  • Stock Options (Right to Buy)

    [F5]
    Exercise: $52.83Exp: 2030-11-01→ Common Stock (38,252 underlying)
    38,252

  • Performance Restricted Stock Units

    [F2][F3]
    → Common Stock (9,423 underlying)
    9,423

  • Performance Stock Options (Right to Buy)

    [F3]
    Exercise: $68.54Exp: 2031-02-01→ Common Stock (25,945 underlying)
    25,945

  • Stock Options (Right to Buy)

    [F6]
    Exercise: $68.54Exp: 2031-02-01→ Common Stock (51,890 underlying)
    51,890

  • Performance Restricted Stock Units

    [F2][F7]
    → Common Stock (51,261 underlying)
    51,261

  • Restricted Stock Units

    [F2][F8]
    → Common Stock (17,087 underlying)
    17,087

  • Stock Options (Right to Buy)

    [F9]
    Exercise: $74.91Exp: 2034-08-15→ Common Stock (69,061 underlying)
    69,061

  • Performance Restricted Stock Units

    [F2][F10]
    → Common Stock (70,708 underlying)
    70,708

  • Restricted Stock Units

    [F2][F11]
    → Common Stock (35,354 underlying)
    35,354

  • Stock Options (Right to Buy)

    [F12]
    Exercise: $53.60Exp: 2035-08-15→ Common Stock (90,441 underlying)
    90,441
Footnotes (12)
  • [F1]Fully exercisable.
  • [F10]Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  • [F11]11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028.
  • [F12]Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
  • [F2]Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • [F3]Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  • [F4]Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026.
  • [F5]Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027.
  • [F6]Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028.
  • [F7]Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  • [F8]8,543 restricted stock units vest on 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027.
  • [F9]Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028.
Signature
/s/ Andrew Nick, Attorney-in-Fact for Kim Kelderman pursuant to Power of Attorney previously filed.|2026-04-24

Documents

1 file
  • 4
    form4.xmlPrimary

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES